BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 28008174)

  • 1. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.
    Gay F; Oliva S; Petrucci MT; Montefusco V; Conticello C; Musto P; Catalano L; Evangelista A; Spada S; Campbell P; Ria R; Salvini M; Offidani M; Carella AM; Omedé P; Liberati AM; Troia R; Cafro AM; Malfitano A; Falcone AP; Caravita T; Patriarca F; Nagler A; Spencer A; Hajek R; Palumbo A; Boccadoro M
    Leukemia; 2017 Aug; 31(8):1727-1734. PubMed ID: 28008174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
    Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
    Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
    Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
    Gössi U; Jeker B; Mansouri Taleghani B; Bacher U; Novak U; Betticher D; Egger T; Zander T; Pabst T
    Hematol Oncol; 2018 Apr; 36(2):436-444. PubMed ID: 29363149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.
    Biran N; Jacobus S; Vesole DH; Callander NS; Fonseca R; Williams ME; Abonour R; Katz MS; Rajkumar SV; Greipp PR; Siegel DS
    Blood Cancer J; 2016 Sep; 6(9):e466. PubMed ID: 27588519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
    Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
    Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
    Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
    Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
    McCarthy PL; Holstein SA; Petrucci MT; Richardson PG; Hulin C; Tosi P; Bringhen S; Musto P; Anderson KC; Caillot D; Gay F; Moreau P; Marit G; Jung SH; Yu Z; Winograd B; Knight RD; Palumbo A; Attal M
    J Clin Oncol; 2017 Oct; 35(29):3279-3289. PubMed ID: 28742454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
    Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
    Goldschmidt H; Baertsch MA; Schlenzka J; Becker N; Habermehl C; Hielscher T; Raab MS; Hillengass J; Sauer S; Müller-Tidow C; Luntz S; Jauch A; Hose D; Seckinger A; Brossart P; Goerner M; Klein S; Schmidt-Hieber M; Reimer P; Graeven U; Fenk R; Haenel M; Martin H; Lindemann HW; Scheid C; Nogai A; Salwender H; Noppeney R; Besemer B; Weisel K;
    Leukemia; 2021 Apr; 35(4):1134-1144. PubMed ID: 32694619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
    Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
    J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma.
    Singh Abbi KK; Zheng J; Devlin SM; Giralt S; Landau H
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):468-72. PubMed ID: 25529381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous transplantation and maintenance therapy in multiple myeloma.
    Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
    N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapsed multiple myeloma: who benefits from salvage autografts?
    Chow AW; Lee CH; Hiwase DK; To LB; Horvath N
    Intern Med J; 2013 Feb; 43(2):156-61. PubMed ID: 22757772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review.
    Al-Ani F; Louzada M
    Eur J Haematol; 2017 Dec; 99(6):479-488. PubMed ID: 28885719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
    Cook G; Royle KL; O'Connor S; Cairns DA; Ashcroft AJ; Williams CD; Hockaday A; Cavenagh JD; Snowden JA; Ademokun D; Tholouli E; Andrews VE; Jenner M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Drayson MT; Brown JM; Morris TCM;
    Br J Haematol; 2019 May; 185(3):450-467. PubMed ID: 30729512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous stem cell transplantation for multiple myeloma: Long-term results.
    Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R
    Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.